Rhabdomyosarcoma (Oncology) - Drugs In Development, 2021

July 2021 | 662 pages | ID: R4860C3EC985EN
Global Markets Direct

Abstracts

Rhabdomyosarcoma (Oncology) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhabdomyosarcoma - Drugs In Development, 2021, provides an overview of the Rhabdomyosarcoma (Oncology) pipeline landscape.

Rhabdomyosarcoma (RMS) is a malignant tumor of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. Symptoms include pain, fever, purplish discoloration of the eye, hearing loss, headaches, bulging of the eye, or a droopy eyelid and tingling or weakness. Predisposing factors include age, inherited conditions (neurofibromatosis type 1, Costello syndrome) and family history. Treatment includes surgery, chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rhabdomyosarcoma - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Rhabdomyosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhabdomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rhabdomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 22, 12, 1, 12 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 1, 1 and 2 molecules, respectively.

Rhabdomyosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma (Oncology).
• The pipeline guide reviews pipeline therapeutics for Rhabdomyosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Rhabdomyosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Rhabdomyosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Rhabdomyosarcoma (Oncology)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Rhabdomyosarcoma (Oncology).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Rhabdomyosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Rhabdomyosarcoma - Overview
Rhabdomyosarcoma - Therapeutics Development
Rhabdomyosarcoma - Therapeutics Assessment
Rhabdomyosarcoma - Companies Involved in Therapeutics Development
Rhabdomyosarcoma - Drug Profiles
Rhabdomyosarcoma - Dormant Projects
Rhabdomyosarcoma - Discontinued Products
Rhabdomyosarcoma - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Rhabdomyosarcoma, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Rhabdomyosarcoma - Pipeline by Abbisko Therapeutics Co Ltd, 2021
Rhabdomyosarcoma - Pipeline by Actuate Therapeutics Inc, 2021
Rhabdomyosarcoma - Pipeline by Advenchen Laboratories LLC, 2021
Rhabdomyosarcoma - Pipeline by Alxerion Biotech Corp, 2021
Rhabdomyosarcoma - Pipeline by Amgen Inc, 2021
Rhabdomyosarcoma - Pipeline by Bayer AG, 2021
Rhabdomyosarcoma - Pipeline by Biogenera SpA, 2021
Rhabdomyosarcoma - Pipeline by Boehringer Ingelheim International GmbH, 2021
Rhabdomyosarcoma - Pipeline by Bristol Myers Squibb Co, 2021
Rhabdomyosarcoma - Pipeline by Cellectar Biosciences Inc, 2021
Rhabdomyosarcoma - Pipeline by Cellestia Biotech AG, 2021
Rhabdomyosarcoma - Pipeline by Eisai Co Ltd, 2021
Rhabdomyosarcoma - Pipeline by Eli Lilly and Co, 2021
Rhabdomyosarcoma - Pipeline by Epizyme Inc, 2021
Rhabdomyosarcoma - Pipeline by Exelixis Inc, 2021
Rhabdomyosarcoma - Pipeline by F. Hoffmann-La Roche Ltd, 2021
Rhabdomyosarcoma - Pipeline by Galapagos NV, 2021
Rhabdomyosarcoma - Pipeline by GlaxoSmithKline Plc, 2021
Rhabdomyosarcoma - Pipeline by ImmunityBio Inc, 2021
Rhabdomyosarcoma - Pipeline by Iproteos SL, 2021
Rhabdomyosarcoma - Pipeline by Ipsen SA, 2021
Rhabdomyosarcoma - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
Rhabdomyosarcoma - Pipeline by MacroGenics Inc, 2021
Rhabdomyosarcoma - Pipeline by Mana Therapeutics Inc, 2021
Rhabdomyosarcoma - Pipeline by Mirati Therapeutics Inc, 2021
Rhabdomyosarcoma - Pipeline by NanoRED Biotechnology, 2021
Rhabdomyosarcoma - Pipeline by Nektar Therapeutics, 2021
Rhabdomyosarcoma - Pipeline by Novartis AG, 2021
Rhabdomyosarcoma - Pipeline by Ohara Pharmaceutical Co Ltd, 2021
Rhabdomyosarcoma - Pipeline by Oncoheroes Biosciences Inc, 2021
Rhabdomyosarcoma - Pipeline by Oncolys BioPharma Inc, 2021
Rhabdomyosarcoma - Pipeline by Onconova Therapeutics Inc, 2021
Rhabdomyosarcoma - Pipeline by PEEL Therapeutics Inc, 2021
Rhabdomyosarcoma - Pipeline by Pfizer Inc, 2021
Rhabdomyosarcoma - Pipeline by Philogen SpA, 2021
Rhabdomyosarcoma - Pipeline by Seneca Therapeutics Inc, 2021
Rhabdomyosarcoma - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2021
Rhabdomyosarcoma - Pipeline by Shepherd Therapeutics Inc, 2021
Rhabdomyosarcoma - Pipeline by Shionogi & Co Ltd, 2021
Rhabdomyosarcoma - Pipeline by Sorrento Therapeutics Inc, 2021
Rhabdomyosarcoma - Pipeline by Taiwan Liposome Co Ltd, 2021
Rhabdomyosarcoma - Pipeline by Tarveda Therapeutics Inc, 2021
Rhabdomyosarcoma - Pipeline by Veana Therapeutics LLC, 2021
Rhabdomyosarcoma - Dormant Projects, 2021
Rhabdomyosarcoma - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Rhabdomyosarcoma, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Top 10 Routes of Administration, 2021
Number of Products by Stage and Top 10 Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021